New drug tested for men with spreading prostate cancer

NCT ID NCT04662580

Summary

This is an early safety study testing a new drug called ARX517 for men with advanced prostate cancer that has spread. The study will see how safe the drug is when given alone or combined with other prostate cancer medications. Researchers will also check how the drug moves through the body and look for early signs that it might help control the cancer.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for METASTATIC PROSTATE CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • Carolina Urologic Research Center

    Myrtle Beach, South Carolina, 29572, United States

  • GU Research Network

    Omaha, Nebraska, 68130, United States

  • Indiana University Melvin and Bren Simon Cancer Center

    Indianapolis, Indiana, 46202-5116, United States

  • UC San Diego Moores Cancer Center

    La Jolla, California, 92093, United States

  • UCSF Medical Center at Mission Bay

    San Francisco, California, 94143-2350, United States

  • University Hospitals Cleveland Medical Center

    Cleveland, Ohio, 44106, United States

  • University of California, Los Angeles School of Medicine

    Los Angeles, California, 90095-3000, United States

  • University of Michigan Comprehensive Cancer Center

    Ann Arbor, Michigan, 48109-5000, United States

  • University of Washington

    Seattle, Washington, 98101, United States

  • Washington University St. Louis School Medicine Siteman Cancer Center

    St Louis, Missouri, 63110, United States

  • Weill Cornell Medical College

    New York, New York, 10021-5663, United States

  • Winship Cancer Institute of Emory University

    Atlanta, Georgia, 30322, United States

Conditions

Explore the condition pages connected to this study.